Literature DB >> 31513046

Efficacy of the Fluorescein Tear Breakup Time Test in Dry Eye.

Jerry R Paugh1, June Tse2, Tiffany Nguyen3, Alan Sasai1, Elaine Chen1, Melinda Thomas De Jesus4, Justin Kwan5, Andrew Loc Nguyen6, Marjan Farid7, Sumit Garg7, James V Jester7,8.   

Abstract

PURPOSE: To examine the effects of volume and method on fluorescein tear breakup time (TBUT) values and to evaluate test efficacy in an independent sample free of selection bias.
METHODS: Subjects were assessed using a battery of dry eye tests (DETs). Efficacy study: Subjects were randomized to the DET, standard strip, and liquid NaFl on separate days. A masked examiner measured TBUTs from video recordings. Verification study: Subjects were investigated for efficacy using volumes of 5.0 and 2.0 μL mL of NaFl for TBUT.
RESULTS: Efficacy study: 46 subjects completed the study. Log-transformed TBUTs were significantly different, normal subjects versus dry subjects, for all 3 methods (all P values < 0.001). Area under the curves (AUCs), cut-points, sensitivity, and specificity were 1) DET: 0.873, 4.4 seconds, 0.97, and 0.67, respectively; 2) 2.0 mL: 0.901, 3.22 seconds, 0.90, and 0.87, respectively; and 3) standard strip: 0.912, 3.42 seconds, 0.97, and 0.80, respectively. Verification study: Data splitting analysis for the 2.0 μL data (n = 174 dry subjects and 97 normal subjects) generated an AUC of 0.917 and a cut-point of 6.05 seconds for a sensitivity of 0.87 and a specificity of 0.81. The 5.0 μL sample yielded an AUC of 0.940, with a sensitivity and specificity of 0.92 and 0.83, respectively, at a cut-point of 5.5 seconds.
CONCLUSIONS: Little difference in TBUT was found using the 3 clinical methods with video recordings. Analysis using liquid NaFl suggests that the TBUT test has excellent diagnostic accuracy and that a cut-point of 5.3 to 6.0 seconds is the optimum to differentiate normals from persons with dry eye.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31513046      PMCID: PMC6893123          DOI: 10.1097/ICO.0000000000002148

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   3.152


  31 in total

1.  A comparison of the self-reported dry eye practices of New Zealand optometrists and ophthalmologists.

Authors:  Ally L Xue; Laura E Downie; Susan E Ormonde; Jennifer P Craig
Journal:  Ophthalmic Physiol Opt       Date:  2017-03       Impact factor: 3.117

2.  Knowledge and use of tear film evaluation tests by spanish practitioners.

Authors:  Genís Cardona; Carme Serés; Lluïsa Quevedo; Montserrat Augé
Journal:  Optom Vis Sci       Date:  2011-09       Impact factor: 1.973

Review 3.  Dry Eye Syndrome Preferred Practice Pattern®.

Authors:  Esen K Akpek; Guillermo Amescua; Marjan Farid; Francisco J Garcia-Ferrer; Amy Lin; Michelle K Rhee; Divya M Varu; David C Musch; Steven P Dunn; Francis S Mah
Journal:  Ophthalmology       Date:  2018-10-23       Impact factor: 12.079

4.  Tear osmolarity in the diagnosis and management of dry eye disease.

Authors:  Michael A Lemp; Anthony J Bron; Christophe Baudouin; José M Benítez Del Castillo; David Geffen; Joe Tauber; Gary N Foulks; Jay S Pepose; Benjamin D Sullivan
Journal:  Am J Ophthalmol       Date:  2011-02-18       Impact factor: 5.258

5.  The Effect of instilled fluorescein solution volume on the values and repeatability of TBUT measurements.

Authors:  Michael E Johnson; Paul J Murphy
Journal:  Cornea       Date:  2005-10       Impact factor: 2.651

6.  Evaluation of subjective assessments and objective diagnostic tests for diagnosing tear-film disorders known to cause ocular irritation.

Authors:  S C Pflugfelder; S C Tseng; O Sanabria; H Kell; C G Garcia; C Felix; W Feuer; B L Reis
Journal:  Cornea       Date:  1998-01       Impact factor: 2.651

7.  Tear cytokine profiles in dysfunctional tear syndrome.

Authors:  Helene Lam; Lauren Bleiden; Cintia S de Paiva; William Farley; Michael E Stern; Stephen C Pflugfelder
Journal:  Am J Ophthalmol       Date:  2008-11-07       Impact factor: 5.258

8.  Quantitative in vitro comparison of fluorescein delivery to the eye via impregnated paper strip and volumetric techniques.

Authors:  Ahmad M Abdul-Fattah; Hridaya N Bhargava; Donald R Korb; Thomas Glonek; Victor M Finnemore; Jack V Greiner
Journal:  Optom Vis Sci       Date:  2002-07       Impact factor: 1.973

Review 9.  Meibomian gland disease. Classification and grading of lid changes.

Authors:  A J Bron; L Benjamin; G R Snibson
Journal:  Eye (Lond)       Date:  1991       Impact factor: 3.775

10.  Repeatability and Reproducibility of Noninvasive Keratograph 5M Measurements in Patients with Dry Eye Disease.

Authors:  Lei Tian; Jing-Hao Qu; Xiao-Yu Zhang; Xu-Guang Sun
Journal:  J Ophthalmol       Date:  2016-04-12       Impact factor: 1.909

View more
  4 in total

1.  The Efficacy of Clinical Tests to Diagnose Evaporative Dry Eye Disease Related to Meibomian Gland Dysfunction.

Authors:  Jerry R Paugh; Tiffany Nguyen; Alan Sasai; Elaine Chen; Melinda Thomas De Jesus; Justin Kwan; Andrew Loc Nguyen; Marjan Farid; Sumit Garg; James V Jester
Journal:  J Ophthalmol       Date:  2022-02-10       Impact factor: 1.909

2.  Validation of the Modified Schein Dry Eye Symptom Questionnaire and Comparison With the Ocular Surface Disease Index.

Authors:  Jerry R Paugh; Elaine Chen; Justin Kwan; Tiffany Nguyen; Alan Sasai; Melinda Thomas De Jesus; Andrew Loc Nguyen; Michael T Christensen; David Meadows
Journal:  Transl Vis Sci Technol       Date:  2022-02-01       Impact factor: 3.283

3.  A Practical Approach to Severity Classification and Treatment of Dry Eye Disease: A Proposal from the Mexican Dry Eye Disease Expert Panel.

Authors:  Alejandro Rodriguez-Garcia; Alejandro Babayan-Sosa; Arturo Ramirez-Miranda; Concepcion Santa Cruz-Valdes; Everardo Hernandez-Quintela; Julio C Hernandez-Camarena; Nallely Ramos-Betancourt; Regina Velasco-Ramos; Raul E Ruiz-Lozano
Journal:  Clin Ophthalmol       Date:  2022-04-28

4.  Impact of meibomian gland dysfunction on quality of life and mental health in a clinical sample in Ghana: a cross-sectional study.

Authors:  Kofi Asiedu; Selassie Dzasimatu; Samuel Kyei
Journal:  BMJ Open       Date:  2022-09-30       Impact factor: 3.006

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.